The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Study Overview

This research study is studying a combination of drugs as a possible treatment for breast cancer.

The drugs involved in this study are:

  • Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine)
  • Group B: Trastuzumab + Vinorelbine + Avelumab
  • Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

Study Description

AVIATOR: A randomized, phase II study comparing trastuzumab and vinorelbine in combination with avelumab or avelumab and utomilumab (41BB/CD137 agonist), in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab and pertuzumab

  • Identifier: NCT03414658
  • Protocol Number: 17-455

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000